# US 2016/0249941 A1 · Non-lithotripsic kidney-stone therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0249941 A1
- Document ID: US20160249941A1
- Status: Published application
- Kind: A1
- Application number: 14/869,335
- Filed: 2015-09-29
- Published: 2016-09-01
- Earliest claimed: 2006-04-27
- Assignees: Genzyme Corporation; The General Hospital Corporation
- Applicants: Genzyme Corporation; The General Hospital Corporation
- Inventors: W. Scott McDougal; Dianne E. Sacco; Alexander Schwarz; Jean-Marie Vogel
- Web page: https://patentgrep.com/patent/US20160249941A1

## CPC

- A61B 17/22: Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B 17/32056: {Surgical snare instruments (for removing or smashing calculi A61B2017/2212; tonsillotomes A61B17/26)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 13/04: for urolithiasis
- A61P 13/12: of the kidneys
- A61B 2017/00818: {Treatment of the gastro-intestinal system}
- A61B 2017/00849: {with respect to tissue, e.g. hollow organs}
- A61B 2017/00853: {low friction, hydrophobic and corrosion-resistant fluorocarbon resin coating (ptf, ptfe, polytetrafluoroethylene)}
- A61B 2017/22037: {Fecal impaction removal}
- A61B 2017/22082: {after introduction of a substance}
- A61B 2018/005: {Rectum}
- A61B 2018/00511: {Kidney}
- A61L 2400/06: Flowable or injectable implant compositions
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.

## Claims

### Claim 1

A method of treating lithiasis, comprising the steps of:
injecting into a lumen of a mammal at a first distance upstream from a calculi a first composition comprising between 12 and 25 weight percent of an inverse thermosensitive polymer, wherein said first composition does not initially contact said calculi; thereby forming a polymer plug; and removing the calculi from the lumen by movement of the polymer plug by peristalsis to traverse said lumen, thereby forcing said calculi from said lumen.

### Claim 2 (depends on 1)

The method of claim 1, further comprising injecting into said lumen a second composition at a second distance upstream from said calculi wherein said second composition does not contact said calculi.

### Claim 3 (depends on 1)

The method of claim 1, wherein said first distance is between about 1 cm and about 5 cm upstream of said calculi.

### Claim 4 (depends on 2)

The method of claim 2, wherein the distance between said first distance and said second distance is less than about 3 mm.

### Claim 5 (depends on 1)

The method of claim 1, wherein said first composition is injected into said lumen through a percutaneous access device.

### Claim 6 (depends on 1)

The method of claim 1, wherein said lumen is or is a portion of a kidney, gall bladder, ureter, urinary bladder, pancreas, salivary gland, small intestine, or large intestine.

### Claim 7 (depends on 1)

The method of claim 1, wherein said lumen is or is a portion of a ureter or kidney.

### Claim 8 (depends on 1)

The method of claim 1, wherein said calculi is a kidney stone, pancreatic stone, salivary stone, or biliary stone.

### Claim 9 (depends on 1)

The method of claim 1, wherein said calculi is a kidney stone.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein said second composition comprises a contrast-enhancing agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.

### Claim 13 (depends on 1)

The method of claim 1, wherein said inverse thermosensitive polymer is an optionally purified poloxamer or poloxamine.

### Claim 14 (depends on 1)

The method of claim 1, wherein said inverse thermosensitive polymer is optionally purified and selected from the group consisting of poloxamine 1107, poloxamine 1307, poloxamer 338 and poloxamer 407.

### Claim 15 (depends on 1)

The method of claim 1, wherein said inverse thermosensitive polymer is an optionally purified poloxamer 407.

### Claim at position 16

16-21. (canceled)
